- Home
- ALLO vs GHY Comparison
ALLO vs GHY Comparison
Compare ALLO & GHY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ALLO | GHY |
|---|---|---|
| Founded | 2017 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 452.6M | 445.2M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | ALLO | GHY |
|---|---|---|
| Price | $1.29 | $10.79 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | ★ 6.3M | 189.9K |
| Earning Date | 11-09-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.58% |
| EPS Growth | ★ 34.09 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $223.15 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.04 | $10.57 |
| 52 Week High | $4.46 | $12.96 |
Technical Indicators
Market Signals| Indicator | ALLO | GHY |
|---|---|---|
| Relative Strength Index (RSI) | 37.19 | 45.47 |
| Support Level | $1.22 | $10.62 |
| Resistance Level | $2.22 | $10.90 |
| Average True Range (ATR) | 0.08 | 0.13 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 43.75 | 66.22 |
Price Performance
Historical ComparisonAbout ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
About GHY PGIM Global High Yield Fund Inc.
PGIM Global High Yield Fund, Inc is a diversified, closed-end management investment company. The fund's investment objective is to provide a high level of current income. The fund seeks to provide a high level of current income by investing in higher-rated, below-investment-grade fixed income instruments of issuers located around the world, including emerging markets.